NCT02944227View on ClinicalTrials.gov

Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

February 16, 2017

Study Completion Date

August 21, 2017

Conditions
Wet Macular Degeneration
Interventions
DRUG

Lucentis

Lucentis fixed-treatment arm

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02944227 - Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter